Ticker Details
Neurocrine Biosciences, Inc. Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
IPO Date:	May 23, 1996
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$15.51B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.01 | 2.18%
Avg Daily Range (30 D):	$3.61 | 2.09%
Avg Daily Range (90 D):	$2.88 | 1.80%

Institutional Daily Volume
Avg Daily Volume:	.7M
Avg Daily Volume (30 D):	1.11M
Avg Daily Volume (90 D):	1M

Trade Size
Avg Trade Size (Sh.):	89
Avg Trade Size (Sh.) (30 D):	47
Avg Trade Size (Sh.) (90 D):	45

Institutional Trades
Total Institutional Trades:	12,562
Avg Institutional Trade:	$4.22M
Avg Institutional Trade (30 D):	$11.35M
Avg Institutional Trade (90 D):	$11.84M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$10.19M
Avg Closing Trade (30 D):	$29.71M
Avg Closing Trade (90 D):	$33.58M
Avg Closing Volume:	103.46K

News

Aug 7, 2026 @ 6:30 AM Nxera Pharma Operational Highlights and Consolidat... Source: Nxera Pharma

Jun 10, 2026 @ 8:44 PM Tom Lee's Small-Cap Granny Shots ETF Reloads: Firs... Source: Chandrima Sanyal

May 1, 2026 @ 6:36 AM Nxera Pharma Operational Highlights and Consolidat... Source: Nxera Pharma

Apr 12, 2026 @ 11:30 PM Nxera Pharma’s Partner Neurocrine Bioscienc... Source: Na

Apr 6, 2026 @ 8:20 PM Why Soleno Therapeutics Stock Rocketed Higher on M... Source: Eric Volkman

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$7.05	$1.43	$1.97
Diluted EPS	$6.82	$1.39	$1.91
Revenue	$3.37B	$959M	$814.5M
Gross Profit			$800.7M
Net Income / Loss	$705.5M	$144.4M	$197.9M
Operating Income / Loss	$794.8M	$151.5M	$193.4M
Cost of Revenue			$13.8M
Net Cash Flow	$66.9M	$64.4M	$-446.5M
PE Ratio